

Listing of Claims:

1
38. (Previously presented): A method for enhancing the formation of a solid, non-migratory coherent mass at a selected vascular site of a mammal which method comprises:

- (a) placing a delivery device having an ejection port at a selected vascular site in a mammal;
- (b) delivering through the ejection port of the delivery device a composition capable of embolizing an aneurysm at a vascular site comprising:
 - a. a biocompatible polymer at a concentration of from about 12 to about 50 weight percent based on the total weight of the composition;
 - b. a biocompatible contrast agent wherein a sufficient amount of said contrast agent is employed in said composition to effect visualization in vivo; and
 - c. a biocompatible solvent which solubilizes said biocompatible polymer;

wherein sufficient amounts of said polymer are employed in said composition such that upon delivery to said vascular site a polymer precipitate forms which embolizes said vascular site;

and further wherein the biocompatible polymer has a molecular weight and/or concentration sufficient to impart to the composition a viscosity of at least about 150 cSt at 40 °C.

2
39. (Previously presented): A method for enhancing the formation of a solid, non-migratory coherent mass at a selected vascular site of a mammal which method comprises:

- (a) placing a delivery device having an ejection port at a selected vascular site in a mammal;
- (b) delivering through the ejection port of the delivery device a composition capable of embolizing an aneurysm at a vascular site comprising:
 - a) a biocompatible polymer at a concentration of from about 12 to about 50 weight percent;

b) a biocompatible contrast agent at a concentration of from about 10 to about 40 weight percent; and

c) a biocompatible solvent from about 10 to 88 weight percent;

wherein the weight percents of the biocompatible polymer, contrast agent, and biocompatible solvent are based on the total weight of the composition;

and further wherein the biocompatible polymer has a molecular weight and/or concentration sufficient to impart to the composition a viscosity of at least about 150 cSt at 40 °C.

3 40. (Previously presented): The method according to Claim ~~28~~ or Claim ~~29~~ wherein, prior to (b) above, a blood flow attenuation device is inserted immediately upstream the ejection port of said catheter.

4 41. (Previously presented): The method according to Claim ~~20~~ wherein, said blood flow attenuation device is an inflatable microballoon which permits both normal and attenuated blood flow depending upon whether the microballoon is deflated or inflated.

5 42. (Previously presented): The method according to Claim ~~28~~ or Claim ~~29~~ wherein said composition has a viscosity of at least about 200 cSt at 40 °C.

6 43. (Previously presented): The method according to Claim ~~42~~ wherein said composition has a viscosity of at least about 500 cSt at 40 °C.

7 44. (Previously presented): The method according to Claim ~~45~~ wherein said composition has a viscosity of from about 500 to 5,000 cSt at 40 °C.

8 45. (Previously presented): The method according to Claim ~~28~~ or Claim ~~29~~ wherein said composition has a migration distance from the point of injection of less than 25 mm.

9 1 2
46. (Previously presented): The method according to Claim 38 or Claim 39 wherein said biocompatible solvent is selected from the group consisting of ethyl lactate, dimethylsulfoxide, ethanol and acetone.

10 1 2
47. (Previously presented): The method according to Claim 46 wherein said biocompatible solvent is dimethylsulfoxide.

11 1 2
48. (Previously presented): The method according to Claim 38 or Claim 39 wherein said contrast agent is a water insoluble contrast agent.

12 1 2
49. (Previously presented): The method according to Claim 48 wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum oxide, tungsten and barium sulfate.

13 1 2
50. (Previously presented): The method according to Claim 49 wherein said contrast agent is tantalum.

14 1 2
51. (Previously presented): The method according to Claim 38 or Claim 39 wherein said contrast agent is a water soluble contrast agent.

15 1 2
52. (Previously presented): The method according to Claim 38 or Claim 39 wherein said biocompatible polymer is a non-biodegradable, biocompatible polymer.

16 1 2
53. (Previously presented): The method according to Claim 52 wherein said non-biodegradable, biocompatible polymer is selected from the group consisting of cellulose acetates, ethylene vinyl alcohol copolymers, hydrogels, polyacrylonitrile, polyvinylacetate, cellulose

acetate butyrate, nitrocellulose, copolymers of urethane/carbonate, copolymers of styrene/maleic acid, and mixtures thereof.

17

16

54. (Previously presented): The method according to Claim 33 wherein said biocompatible polymer is an ethylene and vinyl alcohol copolymer.

18

1

2

55. (Previously presented): The method according to Claim 28 or Claim 39 wherein said biocompatible polymer is a biodegradable, biocompatible polymer.